Novugen

Novugen is a leading pharmaceutical company and wholly owned subsidiary of SciTech International, a UAE-based group with over 30 years of global pharmaceutical expertise. We specialize in developing niche, technology-intensive, first-to-market innovative generics and oncology medicines that meet stringent global quality standards.

Pioneer in ASEAN & International Markets

Novugen is the first vertically integrated pharmaceutical company in ASEAN—seamlessly integrating API and Finished Product R&D, advanced manufacturing, and global commercialization. Our manufacturing facilities in Malaysia include the country’s first and Southeast Asia’s only USFDA-approved pharmaceutical and oncology manufacturing facilities. Our manufacturing facilities are also Halal-certified by JAKIM.

From Malaysia to the World: Accelerating Access to Affordable Medicine

Novugen is currently Malaysia’s fastest-growing pharmaceutical company, with an expanding portfolio of over 280 products across 13 countries. Our medicines are trusted by over 5,000 hospitals, clinics, and pharmacies nationwide.

In 2024, Novugen became the first company in Southeast Asia to export oncology generics to the United States and the first to successfully manufacture and launch a Malaysian-made pharmaceutical product in the country.

With a rapidly growing presence across the United States, ASEAN, MENA, and LATAM regions, Novugen continues to provide life-changing healthcare solutions through scientific innovation, manufacturing excellence, and strategic partnerships—challenging the status quo by accelerating early access to affordable, high-quality medicines worldwide.

Disclaimer:

This page is for general informational and corporate communications purposes and does not provide medical advice. Please consult a qualified healthcare professional for any medical concerns. We reserve the right to remove comments that are inappropriate, misleading, or non-compliant with applicable policies or regulations.